cyc065
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02552953)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CDK2/CDK4INHIBITOR
CDK2/CDK4 inhibitor
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cyc065
- cyc065
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05817890 | Early Phase 1 (Phase 1) | Mar 3, 2023 | Cyclacel Pharmaceuticals, Inc. |
| NCT05168904 | Phase 1/Phase 2 (Phase 2) | Oct 22, 2021 | Cyclacel Pharmaceuticals, Inc. |
| NCT04983810 | Phase 1/Phase 2 (Phase 2) | Jul 12, 2021 | Cyclacel Pharmaceuticals, Inc. |
| NCT04017546 | Phase 1 | Jul 17, 2019 | Cyclacel Pharmaceuticals, Inc., University of Texas at Houston |
| NCT03739554 | Phase 1 | Jan 25, 2019 | Cyclacel Pharmaceuticals, Inc., University of Texas at Houston |
| NCT02552953 | Phase 1 | Sep 1, 2015 | Cyclacel Pharmaceuticals, Inc., Harvard University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | For profit | 6 | 6 | 2 | 2015 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1